[go: up one dir, main page]

PL1622639T3 - Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu - Google Patents

Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu

Info

Publication number
PL1622639T3
PL1622639T3 PL04730516T PL04730516T PL1622639T3 PL 1622639 T3 PL1622639 T3 PL 1622639T3 PL 04730516 T PL04730516 T PL 04730516T PL 04730516 T PL04730516 T PL 04730516T PL 1622639 T3 PL1622639 T3 PL 1622639T3
Authority
PL
Poland
Prior art keywords
plasminogen
intravenous injection
treating cerebral
cerebral stroke
neurotoxic
Prior art date
Application number
PL04730516T
Other languages
English (en)
Inventor
Mariola Söhngen
Wolfgang Söhngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
Lundbeck H As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/004729 external-priority patent/WO2004096267A1/de
Application filed by Lundbeck H As filed Critical Lundbeck H As
Publication of PL1622639T3 publication Critical patent/PL1622639T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • A61K38/58Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04730516T 2003-05-02 2004-04-30 Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu PL1622639T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP03/04608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (de) 2003-05-02 2003-05-06 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
PCT/EP2004/004626 WO2004096268A2 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
EP04730516A EP1622639B1 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall

Publications (1)

Publication Number Publication Date
PL1622639T3 true PL1622639T3 (pl) 2013-06-28

Family

ID=35610451

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04730516T PL1622639T3 (pl) 2003-05-02 2004-04-30 Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu

Country Status (10)

Country Link
EP (1) EP1622639B1 (pl)
JP (1) JP2006525270A (pl)
KR (1) KR101212631B1 (pl)
BR (1) BRPI0409865A (pl)
CA (1) CA2524573A1 (pl)
HR (1) HRP20050903B1 (pl)
NO (1) NO337485B1 (pl)
NZ (1) NZ543367A (pl)
PL (1) PL1622639T3 (pl)
WO (1) WO2004096268A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
US8030350B2 (en) 2005-02-24 2011-10-04 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
EP1897554A1 (en) * 2006-08-25 2008-03-12 PAION Deutschland GmbH Method for the manufacture of a medicament for treating hemorrhagic stroke
WO2008022801A1 (en) * 2006-08-25 2008-02-28 Paion Deutschland Gmbh Method for the manufacture of a medicament for treating hemorrhagic stroke
MX2009010988A (es) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica.
BRPI1010718A2 (pt) 2009-06-10 2016-03-15 Nono Inc sistemas modelo e regimes de tratamento para tratar doença neurológica.
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
JP5823672B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
KR102022116B1 (ko) 2011-06-24 2019-09-18 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI100403B (fi) * 1988-07-20 1997-11-28 Schering Ag Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
WO2004096268A2 (de) 2004-11-11
KR101212631B1 (ko) 2012-12-14
EP1622639B1 (de) 2013-01-16
NO20055692D0 (no) 2005-12-01
JP2006525270A (ja) 2006-11-09
HRP20050903B1 (hr) 2013-11-22
NZ543367A (en) 2010-06-25
NO337485B1 (no) 2016-04-25
WO2004096268A3 (de) 2005-04-21
NO20055692L (no) 2006-01-30
HRP20050903A2 (en) 2006-08-31
BRPI0409865A (pt) 2006-05-16
KR20060020616A (ko) 2006-03-06
EP1622639A2 (de) 2006-02-08
CA2524573A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
PL1622639T3 (pl) Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu
IL173439A0 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP1859914A4 (en) METHOD FOR ADJUSTING THE CASTING CONDITIONS AND METHOD FOR CONTROLLING AN INJECTION MOLDING MACHINE
PL372211A1 (pl) Tiazolilomoczniki w leczeniu raka
IL174951A0 (en) Method for the production of amino crotonyl compounds
IL183973A0 (en) Spm 927 for add -on therapy of schizophrenia
ZA200701583B (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
AU2003295537A8 (en) Methods of treating cerebral ischemia
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
IL175014A0 (en) Method of administering therapeutic injections
ZA200703704B (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AU2002350660A1 (en) Non-neurotoxic plasminogen activating factors for treating stroke
SI1697383T1 (sl) Postopek za čiščenje takrolimusa
AU2003296705A8 (en) Method for controlling the production of injection molded parts
AU2003213596A8 (en) Intraspinal continuous infusion of midazolam hydrochloride for the treatment of pain
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
ZA200603153B (en) Pyridine compounds as inhibitors of dipetidyl peptidase IV
IL174369A0 (en) Methods for treating bladder dysfunction
GB2419843B (en) Process control for gas-assisted injection molding applications
IL156566A0 (en) Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
TW569918U (en) Auxiliary jig for forming mold of needle injecting type label piece
GB2401573B (en) Needle assembly for gas-assisted injection moulding
PL1670841T3 (pl) Sposób wytwarzania mieszanin polioli
TW549219U (en) Support sliding seat for fully injecting seat of injecting forming machine
SI1519726T1 (sl) Heteroarenski karboksamidi za uporabo kot ligandi dopamina D3 za zdravljenje bolezni CŽS